Efficacy and safety of once-weekly semaglutide versus daily canagliflozin as add-on to metformin in patients with type 2 diabetes (SUSTAIN 8): a double-blind, phase 3b, randomised controlled trial

Citation
Lingvay I, Catarig AM, Frias JP, et al. Lancet Diabetes Endocrinol 2019;7:834–44.